	US 12,295,979 B2
	Immuno-modulated replication-efficient Vaccinia virus strain
Gerd Sutter, Munich (DE); and Juan José Rojas Exposito, Munich (DE)
Assigned to Juan José Rojas Exposito, Munich (DE); and Marion Dorothea Kristin-Sutter, Munich (DE)
Filed by Gerd Sutter, Munich (DE); and Juan José Rojas Exposito, Munich (DE)
Filed on Mar. 28, 2023, as Appl. No. 18/191,625.
Application 18/191,625 is a continuation of application No. 16/768,489, granted, now 11,633,441, previously published as PCT/EP2018/083318, filed on Dec. 3, 2018.
Claims priority of application No. 10 2017 128 538.5 (DE), filed on Dec. 1, 2017.
Prior Publication US 2023/0346863 A1, Nov. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/768 (2015.01); A61K 39/00 (2006.01); C12N 7/00 (2006.01)

CPC A61K 35/768 (2013.01) [A61K 39/0011 (2013.01); C12N 7/00 (2013.01); A61K 2039/585 (2013.01); C12N 2710/24121 (2013.01); C12N 2710/24132 (2013.01); C12N 2710/24134 (2013.01)]

13 Claims

1. A genetically modified, immuno-modulating Vaccinia Virus, wherein the virus has a functionally active K1L open reading frame and a functionally inactive A56R open reading frame, wherein the virus is replication competent in mammalian cells and causes calreticulin translocation to the membrane of an infected HeLa cell.